Loading…
The combination aims to enhance Glucotrack's product offerings.
Glucotrack, Inc. (Nasdaq: GCTK) and Lōkahi Therapeutics have finalized a strategic business combination. The transaction was completed to leverage Lōkahi Therapeutics' expertise and product pipeline, aiming to bolster Glucotrack's position in the medical devices sector.
No financial amounts or share considerations were disclosed in the announcement. The combination is expected to provide Glucotrack with additional resources and capabilities.
As of the latest available data, Glucotrack has a free float of 565,410 shares and 6,259,279 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.